Abstract: The present invention provides methods for treating cancer in a subject, comprising administering to the subject an effective amount of a combination of andrographolide and melatonin. The present invention further provides compositions comprising effective amounts of andrographolide and melatonin for treating cancer.

Abstract: Drug delivery to the cancer cells during its treatment is challenging. Most of the cancer drug cannot reach to the target because of its complex membrane physiology, drug resistance, and mutability. Establishment of a potential target molecule or domain on the cancer cell is the rate limiting step for the successful drug delivery. Cancer is characterized by abnormal energy metabolism shaped by nutrient deprivation that malignant cells experience during various stages of tumor development. This patent demonstrated a new method of establishing a new target domain that could have enormous importance for the drug delivery during cancer treatment. The inventors showed how nutrient-deprived cancer cells become involved in robust membrane glycan display while treating with nucleotide sugar such as sialic acid and that glycosylated membrane domain become a target domain of cancer cell treatment.

Abstract: A brake pad assembly includes a backing plate having a first surface and a second surface opposite the first surface, a brake liner coupled to the first surface of the backing plate and configured to engage a braking surface, and a shim coupled to the second surface of the backing plate, the shim including a planar body portion and a plurality of tabs integrally formed with and extending from the planar body portion. A first tab of the plurality of tabs is configured to secure the shim to the backing plate and to engage the braking surface when the brake liner is worn a predetermined amount.

Abstract: A Thomsen-Friedenreich disaccharide-containing glycopeptide purified from cod fish of approximately 100 kDa (designated TFD100) and methods of using the same in the suppression of cancer metastasis is disclosed.

Abstract: A brake pad assembly includes a backing plate having a first surface and a second surface opposite the first surface, a brake liner coupled to the first surface of the backing plate and configured to engage a braking surface, and a shim coupled to the second surface of the backing plate, the shim including a planar body portion and a plurality of tabs integrally formed with and extending from the planar body portion. A first tab of the plurality of tabs is configured to secure the shim to the backing plate and to engage the braking surface when the brake liner is worn a predetermined amount.

Abstract: A Thomsen-Friedenreich disaccharide-containing glycopeptide purified from cod fish of approximately 100 kDa (designated TFD100) and methods of using the same in the suppression of cancer metastasis is disclosed.

Abstract: A method and assay are described for determining prostate cancer and the general stage of progression of such cancer by quantifying levels of promoter methylation of gal-3, optionally in combination with the quantification of the level of GSTP1 promoter methylation, where the method and assay are non-invasive to a subject and can detect any of Stages I-IV prostate cancer.

Abstract: A method and assay are described for determining prostate cancer and the general stage of progression of such cancer by quantifying levels of expression of different galectin isoforms and/or different levels of promoter methylation of such galectin isoforms.

Abstract: A method and assay are described for determining prostate cancer and the general stage of progression of such cancer by quantifying levels of promoter methylation of gal-3, optionally in combination with the quantification of the level of GSTP1 promoter methylation, where the method and assay are non-invasive to a subject and can detect any of Stages I-IV prostate cancer.

Abstract: A method and assay are described for determining prostate cancer and the general stage of progression of such cancer by quantifying levels of expression of different galectin isoforms and/or different levels of promoter methylation of such galectin isoforms.